Back to Market返回行情

XBI State Street SPDR S&P Biotech ETF

AMEXETF
$159.03-3.20%ClosedAssets: $8.31B

As of 2026-07-10 16:00

Why XBI matters now

State Street SPDR S&P Biotech ETF (XBI) is a US etf in Financial Services. The latest InvestLog snapshot shows $159.03 with -3.20% on the session and $8.31B in assets/market value.

The latest indexable market news headline is "Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?" from The Motley Fool.

ETF Profile

Updated 2026-07-10

Net Assets

$11.10B

NAV

$164.25

Expense Ratio

0.35%

Holdings

157

Issuer

SPDR

Asset Class

Equity

Avg Volume

8,792,375

Inception

2006-01-31

Sector Exposure

Financial Services0.33%
Healthcare99.67%

Top Holdings

SymbolNameWeightMarket Value
MRNAMODERNA INC1.49%$165.1M
APGEAPOGEE THERAPEUTICS INC1.44%$160.2M
KYMRKYMERA THERAPEUTICS INC1.36%$150.9M
VKTXVIKING THERAPEUTICS INC1.32%$147.1M
ERASERASCA INC1.28%$142.3M
PRAXPRAXIS PRECISION MEDICINES I1.24%$137.3M
TWSTTWIST BIOSCIENCE CORP1.23%$137.1M
ORKAORUKA THERAPEUTICS INC1.23%$136.8M
MIRMMIRUM PHARMACEUTICALS INC1.21%$134.8M
RYTMRHYTHM PHARMACEUTICALS INC1.20%$133.7M

Fund Info

Asset Type

ETF

Exchange

AMEX

Currency

USD

Issuer

SPDR

Asset Class

Equity

NAV Currency

USD

SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.